This conference report summarizes discussions at a March 2018 conference in Washington with 30 leaders from the health care community to launch Initiative 18/11, a partnership between the Society of Actuaries and KFF to address the rising cost of health care in the United States. It also lays out the next steps for the initiative.
- view as grid
- view as list
An archived webcast of this forum is now available at http://www.healthsystemtracker.org . Nearly a fifth of the United States’ economy goes to healthcare spending – a far larger share than in any other large, wealthy country in the world. Research suggests that price, rather than the volume of services, is…
Web Event: Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs
On Wednesday, October 5, from noon to 1 p.m. ET, the Kaiser Family Foundation will host a web conversation to discuss proposals for controlling prescription drug costs, examine pros and cons of the ideas, and assess the likelihood that the plans will be enacted.
Web Event: Rx Drugs and the U.S. Health System: A Conversation about Medicare Prescription Drug Costs
On Wednesday, September 7, from noon to 1 p.m. ET, the Kaiser Family Foundation hosted a web conversation to discuss trends in Medicare prescription drug spending, as well as proposals to reduce costs and forecasts of what beneficiaries can expect in coming years.
The Kaiser Family Foundation will host a web conversation to discuss the drivers of recent and forecasted trends in prescription drug spending and examine how drug prices are set.
This Visualizing Health Policy infographic spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices. Prescription drug spending rose sharply in 2014, driven by growth in expenditures on specialty drugs, including medications to treat cancer and hepatitis C. Medicare’s spending on prescription pharmaceuticals also has risen, largely…
National health spending started to grow more rapidly recently after several years of unusually slow growth. This analysis from the Kaiser Family Foundation and the federal Bureau of Economic Analysis helps to dissect why that may be happening. Using recently-released disease-based health spending data compiled by the federal government, the analysis finds…
In this column for The Wall Street Journal’s Think Tank, Drew Altman explores the data behind public concern about prescription drug costs and highlights that the people most in need are the most burdened by the problem.
In his latest column for The Wall Street Journal‘s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it. All previous columns by Drew Altman are online.
In this column for The Wall Street Journal’s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it.